Citius Oncology (NASDAQ:CTOR) Stock Price Down 2.5% – What’s Next?

Citius Oncology, Inc. (NASDAQ:CTOR) shares were down 2.5% during trading on Friday . The company traded as low as $1.15 and last traded at $1.17. Approximately 45,075 shares were traded during trading, a decline of 55% from the average daily volume of 101,126 shares. The stock had previously closed at $1.20.

Wall Street Analyst Weigh In

Separately, Maxim Group initiated coverage on shares of Citius Oncology in a research note on Wednesday, November 27th. They set a “buy” rating and a $3.00 price objective on the stock.

Citius Oncology Stock Down 2.5 %

The company has a debt-to-equity ratio of 0.08, a quick ratio of 0.08 and a current ratio of 0.34. The company’s fifty day moving average is $1.18.

Citius Oncology (NASDAQ:CTOR) last issued its quarterly earnings results on Friday, February 14th. The company reported ($0.09) earnings per share (EPS) for the quarter.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Citius Oncology stock. Citadel Advisors LLC purchased a new stake in Citius Oncology, Inc. (NASDAQ:CTOR) in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor purchased 22,699 shares of the company’s stock, valued at approximately $26,000. Institutional investors own 70.52% of the company’s stock.

About Citius Oncology

Citius Oncology, Inc is a pharmaceutical company, which engages in developing and commercializing targeted oncology therapies. Its lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma.